Trials / Recruiting
RecruitingNCT06075940
Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia
Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold (BRS)in the Treatment of Patients With Below the Knee Disease in Australia
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- R3 Vascular Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Up to 30 subjects will be enrolled at approximately 3 clinical sites in Australia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MAGNITUDE BRS | Treatment with the MAGNITUDE Scaffold |
Timeline
- Start date
- 2024-03-04
- Primary completion
- 2026-12-31
- Completion
- 2030-12-31
- First posted
- 2023-10-10
- Last updated
- 2024-04-10
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06075940. Inclusion in this directory is not an endorsement.